Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction

Data de publicação:

Autores da FMUP

  • Joaquim Adelino Correia Ferreira Leite Moreira

    Autor

Participantes de fora da FMUP

  • Büttner P.
  • Augstein A.
  • Abdellatif M.
  • Lourenço A.
  • Falcão-Pires I.
  • Werner S.
  • Thiele H.
  • Sedej S.
  • Schauer A.
  • Adams V.

Unidades de investigação

Abstract

Aims: ZSF1 obese rats harbouring two mutant leptin receptor alleles (Leprcp and Leprfa) develop metabolic syndrome and heart failure with preserved ejection fraction (HFpEF), making them a widely used animal model in cardiometabolic research. Studies using ZSF1 rats have contributed significantly to the elucidation of pathophysiological mechanisms underlying HFpEF and therapeutic strategies against this multi-organ syndrome. In contrast, hybrid, lean ZSF1 rats (L-ZSF1) do not develop HFpEF and generally serve as controls, disregarding the possibility that the presence of one mutant Lepr allele might affect left ventricular ejection fraction (LVEF), diastolic dysfunction and other relevant HFpEF parameters, such as N-terminal pro-brain natriuretic peptide (NT-proBNP) levels and cardiac inflammation, which could increase during disease manifestation. Methods and Results: We collected specimens and echocardiography data of male and female L-ZSF1 rats (n = 165; ZSF1-LeprfaLeprcp/Crl) at the age of 6–32 weeks from four independent research groups and performed genotyping as well as the genotype–phenotype analyses. The genotype distribution within L-ZSF1 was in line with the Hardy–Weinberg equilibrium. Genotypes were not associated with CD68 counts (n = 52, P = 0.886), E/e' ratio (n = 125, P > 0.250) and NT-proBNP (n = 126, P = 0.874). LVEF significantly decreased from 25 weeks of age (P = 0.021) but was independent of the genotype (P = 0.768 at <25 weeks of age and P = 0.069 at =25 weeks of age, n = 128). Conclusions: In conclusion, validation of the genotype distribution in L-ZSF1 rats revealed no associations between the genotype and HFpEF-relevant measures, namely, NT-proBNP, CD68 count, LVEF or E/e'. © 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Dados da publicação

ISSN/ISSNe:
2055-5822, 2055-5822

ESC heart failure  The Heart Failure Association of the European Society of Cardiology

Tipo:
Article
Páginas:
-
PubMed:
39663741
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 2

Citações Recebidas na Scopus: 2

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • heart failure with preserved ejection fraction; HFpEF rat model; ZSF1 genotype; ZSF1 rat

Financiamento

Projetos associados

Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684

Investigador Principal: João Pedro Melo Marques Pinho Ferreira

Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022

The Canadian CABG or PCI in Patients with Ischemic Cardiomyopathy Trial (STICH 3C) - NCT05427370

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Ensaio Clínico Académico (STICH 3C) . Cornell University . 2023

Estudo do tratamento da doença valvular aórtica.

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Observacional Académico (AORTA) . UniC . 2019

Eficácia da transposição de um pedículo adiposo pericárdico sobre o enfarte de miocárdio em pacientes (ensaio AGTP II)

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Ensaio Clínico Académico (Ensaio AGTP II) . 2019

Aortic valve surgery with stented versus stentless bioprosthesis in patients with active infective endocarditis

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico (Endocarditis) . 2023

Early Dual Antiplatelet Therapy versus Aspirin Monotherapy after Coronary Artery Bypass Surgery: survival and safety outcomes

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico (Bypass) . 2020

Early and Midterm Outcomes following Aortic Valve Replacement with Mechanical versus Bioprosthetic Valves in Patients aged 50 to 70 Years

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico (Aortic Valve Replacemen) . 2020

Efeito da terapêutica ß-bloqueadora pré-operatória após cirurgia de revascularização do miocárdio: sobrevida e complicações pós-operatórias

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico . 2021

"Aortic valve surgery in patients with infective endocarditis: mid-term follow-up of patients treated with the St. Jude medical trifecta™ valve"

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico . 2022

Long-term survival after coronary artery bypass grafting: the relevance of surgical procedures analysed by propensity score methods.

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico (Arrtery bypass) . 2022

Abdominal Aortic Aneurysm - The Portuguese Case: Specificities and Consequences

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico . 2022

New Insights into Epidemiology and Pathophysiology of Abdominal Aortic Aneurysms

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico . 2021

Impacto clínico e hemodinâmico da substituição cirúrgica da válvula aórtica por biopróteses de última geração

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico . 2020

Condicionamento isquémico cardíaco remoto como adjuvante da revascularização miocárdia na doença coronário aguda

Investigador Principal: Joaquim Adelino Correia Ferreira Leite Moreira

Estudo Clínico Académico . 2020

Citar a publicação

Partilhar a publicação